Skip to main content
MedPathMedPath Home
Clinical Trials/ACTRN12610000802000
ACTRN12610000802000
Not yet recruiting
Phase 4

Impact of Intensive Medical Treatment in Elderly Patients with Left Ventricle Ejection Fraction >40%, Elevated Left Ventricular Volumes and Abnormal Brain Natriuretic Peptide levels Post Acute Myocardial Infarction on new Heart Failure Hospitalisation (INTENSIVE AMI-HF)

PAH0 sites200 target enrollmentSeptember 27, 2010
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHeart FailureCardiovascular - Other cardiovascular diseases

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Heart Failure
Sponsor
PAH
Enrollment
200
Status
Not yet recruiting
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 27, 2010
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
PAH

Eligibility Criteria

Inclusion Criteria

  • •Adult patients \>60 years old 2 weeks post MI (STEMI, NSTEMI)
  • •LVEF \>40% and
  • •LVESVI\>30ml/m2 or LVEDVI\>75ml/m2 and
  • •BNP \>100ng/l

Exclusion Criteria

  • •Known heart failure
  • •Known LVEF\<40%
  • •Previous MI (except the primary event)
  • •Severe valvular heart disease
  • •Severe life span limiting medical disease (cancer, Chronic Obstructive Pulmonary Disease (COPD) with FEV1\<1\.0 l, renal failure serum Creatinine \>200mcmol/l)
  • •Systolic Blood Pressure \<100mmHg
  • •Lack of consent

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
One Year Outcome of Elderly Patients Admitted to an ICU and Mechanically VentilatedElderly Care
NCT01679171University Hospital, Angers489
Active, not recruiting
Phase 1
Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to a standard chemotherapy.
EUCTR2016-002272-27-BESaarland University388
Active, not recruiting
Phase 1
Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to a standard chemotherapy.Patients with first relapse or progression of aggressive Non-Hodgkin’s Lymphoma who are not eligible neither for autologous nor allogeneic stem cell transplantationMedDRA version: 22.0Level: PTClassification code 10029547Term: Non-Hodgkin's lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2016-002272-27-ATSaarland University388
Active, not recruiting
Phase 1
Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to a standard chemotherapy.
EUCTR2016-002272-27-PTSaarland University388
Active, not recruiting
Phase 1
Improvement of Outcome in Elderly Patients or Patients not eligible forhigh-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma infirst Relapse or Progression by adding Nivolumab to Gemcitabine,Oxaliplatin plus Rituximab in case of B-cell lymphoma.
EUCTR2016-002272-27-PLSaarland University388